Antisoma CEO and finance director leave after pipeline failures

1 March 2011

The chief executive of UK biotech Antisoma, Glyn Edwards, has stepped down in the wake of the recent late-stage failures in the company's clinical pipeline.

Finance director Eric Dodd has also walked, according to a Reuters report, although he is continuing to advise Antisoma on strategic options, which could include the sale of the company.

In January, Antisoma's lead drug candidate AS1413 (amonafide malate) bombed in a Phase III trial involving patients with secondary acute myeloid leukemia after the study missed its primary endpoint, an improvement the complete remission rate with or without recovery of normal blood counts.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK